Tamoxifen with antidepressants may raise risk of breast cancer recurrence
The Food and Drug Administration (FDA) is expected to issue a warming to doctors about an increased risk of the recurrence of breast cancer with patients taking both the breast cancer drug tamoxifen and select antidepressants, according to a study released last week at the American Society of Clinical Oncology’s annual meeting.